Chemical: Drug
vinblastine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for vinblastine

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA GSTM1 non-null N/A N/A N/A
No VIP available CA VA GSTM1 null N/A N/A N/A
No VIP available No VIP available VA GSTT1 non-null N/A N/A N/A
No VIP available No VIP available VA GSTT1 null N/A N/A N/A
No VIP available CA VA
rs2229109 NC_000007.13:g.87179809C>T, NC_000007.14:g.87550493C>T, NG_011513.1:g.167756G>A, NM_000927.4:c.1199G>A, NP_000918.2:p.Ser400Asn, rs17276921, rs2235031, rs386561706, rs59635509
C > T
SNP
S400N
No VIP available CA VA
rs72552784 NC_000007.13:g.87145914C>T, NC_000007.14:g.87516598C>T, NG_011513.1:g.201651G>A, NM_000927.4:c.2995G>A, NP_000918.2:p.Ala999Thr
C > T
SNP
A999T
No VIP available CA VA
rs9282564 NC_000007.13:g.87229440T>C, NC_000007.14:g.87600124T>C, NG_011513.1:g.118125A>G, NM_000927.4:c.61A>G, NP_000918.2:p.Asn21Asp, rs13234342, rs202032114, rs61615398
T > C
SNP
N21D
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
  • Nincaluicolflastine
  • Rozevin
  • Velban
  • Velbe
  • Vinblastin
  • Vinblastina [Dcit]
  • Vinblastine Sulfate
  • Vinblastinum [INN-Latin]
  • Vincaleucoblastin
  • Vincaleucoblastine
  • Vincaleukoblastine
  • Vincoblastine
Brand Mixture Names

PharmGKB Accession Id

PA451877

Type(s):

Drug

Description

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Source: Drug Bank

Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.

Source: Drug Bank

Pharmacology

Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinblastine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. Metabolism of vinblastine has been shown to be mediated by hepatic cytochrome P450 3A isoenzymes.

Source: Drug Bank

Protein Binding

98-99%

Source: Drug Bank

Half-Life

Triphasic: 35 min, 53 min, and 19 hours

Source: Drug Bank

Toxicity

Oral, mouse: LD 50 = 423 mg/kg; Oral, rat: LD 50 = 305 mg/kg.

Source: Drug Bank

Route of Elimination

The major route of excretion may be through the biliary system.

Source: Drug Bank

Chemical Properties

Chemical Formula

C46H58N4O9

Source: Drug Bank

Canonical SMILES

CC[C@]1(O)C[C@H]

Source: Drug Bank

Average Molecular Weight

810.9741

Source: Drug Bank

Monoisotopic Molecular Weight

810.420379474

Source: Drug Bank

SMILES

[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@H]4CN(C[C@](O)(CC)C4)CCC4=C3NC3=CC=CC=C43)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]

Source: Drug Bank

InChI String

InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ABCB1 (source: Drug Bank)
JUN (source: Drug Bank)
TUBA1A (source: Drug Bank)
TUBB (source: Drug Bank)
TUBB2A (source: Drug Bank)
TUBD1 (source: Drug Bank)
TUBE1 (source: Drug Bank)
TUBG1 (source: Drug Bank)

Drug Interactions

Interaction Description
aprepitant - vinblastine Aprepitant may change levels of the chemotherapy agent, vinblastine. (source: Drug Bank)
erythromycin - vinblastine Erythromycin increases vinblastine toxicity (source: Drug Bank)
erythromycin - vinblastine Erythromycin increases vinblastine toxicity (source: Drug Bank)
fluconazole - vinblastine Increases the effect and toxicity of anticancer agent (source: Drug Bank)
fluconazole - vinblastine Increases the effect and toxicity of anticancer agent (source: Drug Bank)
fosphenytoin - vinblastine The antineoplasic agent decreases the effect of hydantoin (source: Drug Bank)
itraconazole - vinblastine The imidazole increases the effect and toxicity of the antineoplasic (source: Drug Bank)
itraconazole - vinblastine The imidazole increases the effect and toxicity of the antineoplasic (source: Drug Bank)
ketoconazole - vinblastine The imidazole increases the effect and toxicity of vinblastine (source: Drug Bank)
ketoconazole - vinblastine The imidazole increases the effect and toxicity of vinblastine (source: Drug Bank)
mitomycin - vinblastine Potentially severe lung toxicity (source: Drug Bank)
mitomycin - vinblastine Potentially severe lung toxicity (source: Drug Bank)
phenytoin - vinblastine The antineoplasic agent decreases the effect of hydantoin (source: Drug Bank)
phenytoin - vinblastine The antineoplasic agent decreases the effect of hydantoin (source: Drug Bank)
quinupristin - vinblastine This combination presents an increased risk of toxicity (source: Drug Bank)
telithromycin - vinblastine Telithromycin may reduce clearance of Vinblastine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank)
trastuzumab - vinblastine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. (source: Drug Bank)
voriconazole - vinblastine Voriconazole may increase the serum concentration and toxicity of vinblastine. Adjust dose of vinblastine and monitor for changes in the therapeutic and adverse effects of vinblastine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to vinblastine: 10

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic analysis in the treatment of Hodgkin lymphoma. Leukemia & lymphoma. 2013. Alt├ęs Albert, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics. 2011. Peters Eric J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer chemotherapy and pharmacology. 2010. Harmsen Stefan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer chemotherapy and pharmacology. 2009. Woodahl Erica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. The Journal of pharmacology and experimental therapeutics. 2008. Yang Ziping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (New York, N.Y.). 2007. Kimchi-Sarfaty Chava, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Molecular pharmacology. 2002. Kimchi-Sarfaty Chava, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer research. 1994. Cole S P, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
55390-091-10
DrugBank:
DB00570
PDB:
KAR
ChEBI:
27375
KEGG Compound:
C07201
PubChem Compound:
241903
PubChem Substance:
156698
46504550
Drugs Product Database (DPD):
2183056
BindingDB:
50012278
ChemSpider:
12773
HET:
KAR
Therapeutic Targets Database:
DAP000785
FDA Drug Label at DailyMed:
b8052de1-dc63-4bac-a2de-b932f6a31bd7

Clinical Trials

These are trials that mention vinblastine and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.